Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- No Serious Concern about Safety of New-Type Flu Vaccines Made in Japan
January 25, 2010
- 26 Listed JPMA Member Companies' Combined Operating Profits Up 28.8% in 1st Half of FY2009
January 25, 2010
- Actemra Approved in the US: Chugai, Roche
January 25, 2010
- Bayer to Transfer Shinbit to Hospira
January 25, 2010
- Pfizer Receives CRL for Lyrica Applied for GAD
January 25, 2010
- Ranbaxy Creates Japanese Subsidiary
January 25, 2010
- Nichi-Iko to Enter the Market for Biosimilars: President Tamura
January 25, 2010
- Mitsui & Co. Embarks on CRO Business in Asia
January 25, 2010
- Latanoprost to See Generics from 23 Companies
January 25, 2010
- New Premium to Trouble Wholesalers Again
January 25, 2010
- Include Prevnar in Periodic Immunization Programs ASAP: Dr Wada
January 25, 2010
- Rate of New Premium for New Drug Development Will Be 5.10%
January 25, 2010
- Eisai to Apply for Eribulin in Japan, the US and Europe in March
January 25, 2010
- 61% of Drug Companies Welcome New Pricing System: Questionnaire
January 25, 2010
- MK-8669 Enters PII in Japan: Banyu
January 25, 2010
- Panel of Experts on Unapproved Drugs/Indications to Be Inaugurated
January 25, 2010
- MBL, Osaka Univ. Isolate Fully-Human Flu Virus MAB
January 25, 2010
- Companies Should Be Encouraged to Participate in New Growth Strategy: Mr Nagatsuma
January 25, 2010
- Tasigna Shown to Be Superior to Glivec for CML: Novartis
January 25, 2010
- Eisai Applies for Pediatric Indication for lecainide Based on Data in Public Domain
January 25, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…